Lirong Zhang
- Cancer Research top 2%
- Cancer-related molecular mechanisms research 16
- MicroRNA in disease regulation 9
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 24
- Molecular Biology top 5%
- RNA modifications and cancer 21
- Epigenetics and DNA Methylation 16
- Cancer-related gene regulation 10
- Ion channel regulation and function 8
- Transplantation top 5%
- Oncology top 5%
- Drug Transport and Resistance Mechanisms 14
- Co-authors
- Shengna HanXu Dong ZhangTao LiuYuan GaoQiang FuDongkui SongQingjuan ChenGenbao Shao
- Journals
- Advanced Materials (1 paper)Nature Communications (1 paper)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Lirong Zhang
191 papers receiving 4.2k citations
Hit Papers
Peers
Comparison fields: 5 of 151
- Cancer Research 882
- Pharmacology 398
- Molecular Biology 2.1k
- Transplantation 74
- Oncology 628
Countries citing papers authored by Lirong Zhang
This map shows the geographic impact of Lirong Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lirong Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lirong Zhang more than expected).
Fields of papers citing papers by Lirong Zhang
This network shows the impact of papers produced by Lirong Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lirong Zhang. The network helps show where Lirong Zhang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lirong Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 6 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 10 | |
| 5 | 2024 | 47 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 9 | |
| 8 | 2024 | 5 | |
| 9 | 2024 | 4 | |
| 10 | 2024 | 8 | |
| 11 | Recent development of multi-target VEGFR-2 inhibitors for the cancer therapybreakdown → | 2023 | 93 |
| 12 | 2023 | 20 | |
| 13 | 2023 | 8 | |
| 14 | 2020 | 9 | |
| 15 | 2019 | 10 | |
| 16 | 2019 | 9 | |
| 17 | Cigarette smoke exposure promotes differentiation of CD4+T cells toward Th17 cells by CD40-CD40L costimulatory pathway in mice | 2018 | 1 |
| 18 | 2016 | 17 | |
| 19 | MRI shows clodronate-liposomes attenuating liver injury in rats with severe acute pancreatitis. | 2010 | 13 |
| 20 | Pharmacokinetics and relative bioavailability of betaxolol hydrochloride tablets in Chinese healthy volunteers | 2007 | 1 |
About Lirong Zhang
Lirong Zhang is a scholar working on Pharmacology, Cancer Research and Transplantation, having authored 202 papers that have together received 4.3k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (24 papers), RNA modifications and cancer (21 papers), Cancer-related molecular mechanisms research (16 papers), Epigenetics and DNA Methylation (16 papers), Drug Transport and Resistance Mechanisms (14 papers), Cancer-related gene regulation (10 papers), MicroRNA in disease regulation (9 papers) and Ion channel regulation and function (8 papers). The work is most often cited by research in Cancer Research (882 citations), Pharmacology (398 citations) and Molecular Biology (2.1k citations). Lirong Zhang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Shengna Han, Xu Dong Zhang, Tao Liu, Yuan Gao, Qiang Fu, Dongkui Song, Qingjuan Chen, Genbao Shao, Yanfang Liu and Xiao‐bo Zhong. Their work appears in journals such as Advanced Materials, Nature Communications and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.